DC Field | Value | Language |
---|---|---|
dc.contributor.author | J H Choi | - |
dc.contributor.author | Jong Gil Park | - |
dc.contributor.author | H J Jeon | - |
dc.contributor.author | M S Kim | - |
dc.contributor.author | M R Lee | - |
dc.contributor.author | M N Lee | - |
dc.contributor.author | S K Sonn | - |
dc.contributor.author | J H Kim | - |
dc.contributor.author | M H Lee | - |
dc.contributor.author | M S Choi | - |
dc.contributor.author | Y B Park | - |
dc.contributor.author | O S Kwon | - |
dc.contributor.author | Tae Sook Jeong | - |
dc.contributor.author | Woo Song Lee | - |
dc.contributor.author | H B Shim | - |
dc.contributor.author | D H Shin | - |
dc.contributor.author | G T Oh | - |
dc.date.accessioned | 2017-04-19T09:25:19Z | - |
dc.date.available | 2017-04-19T09:25:19Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | I000-0028 | - |
dc.identifier.uri | 10.3858/emm.2011.43.8.053 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/10309 | - |
dc.description.abstract | A variety of benzylidenethiazole analogs have been demonstrated to inhibit 5-lipoxygenase (5-LOX). Here we report the anti-atherogenic potential of 5-(4-hydroxy-2,3,5-trimethylbenzylidene) thiazolidin-2,4-dione (HMB-TZD), a benzylidenethiazole analog, and its potential mechanism of action in LDL receptor-deficient (Ldlr-/-) mice. HMB-TZD Treatment reduced leukotriene B4 (LTB4) production significantly in RAW264.7 macrophages and SVEC4-10 endothelial cells. Macrophages or endothelial cells pre-incubated with HMB-TZD for 2 h and then stimulated with lipopolysaccharide or tumor necrosis factor-alpha (TNF-α) displayed reduced cytokine production. Also, HMB-TZD reduced cell migration and adhesion in accordance with decreased proinflammatory molecule production in vitro and ex vivo. HMB-TZD treatment of 8-week-old male Ldlr-/- mice resulted in significantly reduced atherosclerotic lesions without a change to plasma lipid profiles. Moreover, aortic expression of pro-atherogenic molecules involved in the recruitment of monocytes to the aortic wall, including TNF-α, MCP-1, and VCAM-1, was downregulated. HMB-TZD also reduced macrophage infiltration into atherosclerotic lesions. In conclusion, HMB-TZD ameliorates atherosclerotic lesion formation possibly by reducing the expression of proinflammatory molecules and monocyte/macrophage recruitment to the lesion. These results suggest that HMB-TZD, and benzylidenethiazole analogs in general, may have therapeutic potential as treatments for atherosclerosis. | - |
dc.publisher | Springer-Nature Pub Group | - |
dc.title | 5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion | - |
dc.title.alternative | 5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion | - |
dc.type | Article | - |
dc.citation.title | Experimental and Molecular Medicine | - |
dc.citation.number | 8 | - |
dc.citation.endPage | 478 | - |
dc.citation.startPage | 471 | - |
dc.citation.volume | 43 | - |
dc.contributor.affiliatedAuthor | Jong Gil Park | - |
dc.contributor.affiliatedAuthor | Tae Sook Jeong | - |
dc.contributor.affiliatedAuthor | Woo Song Lee | - |
dc.contributor.alternativeName | 최재훈 | - |
dc.contributor.alternativeName | 박종길 | - |
dc.contributor.alternativeName | 전형준 | - |
dc.contributor.alternativeName | 김미순 | - |
dc.contributor.alternativeName | 이미란 | - |
dc.contributor.alternativeName | 이미니 | - |
dc.contributor.alternativeName | 손성근 | - |
dc.contributor.alternativeName | 김재홍 | - |
dc.contributor.alternativeName | 이문한 | - |
dc.contributor.alternativeName | 최명숙 | - |
dc.contributor.alternativeName | 박용복 | - |
dc.contributor.alternativeName | 권오승 | - |
dc.contributor.alternativeName | 정태숙 | - |
dc.contributor.alternativeName | 이우송 | - |
dc.contributor.alternativeName | 심현보 | - |
dc.contributor.alternativeName | 신동해 | - |
dc.contributor.alternativeName | 오구택 | - |
dc.identifier.bibliographicCitation | Experimental and Molecular Medicine, vol. 43, no. 8, pp. 471-478 | - |
dc.identifier.doi | 10.3858/emm.2011.43.8.053 | - |
dc.subject.keyword | Antioxidants | - |
dc.subject.keyword | Arachidonate 5-lipoxygenase | - |
dc.subject.keyword | Atherosclerosis | - |
dc.subject.keyword | Endothelial cells | - |
dc.subject.keyword | Macrophages | - |
dc.subject.local | Antioxidants | - |
dc.subject.local | antioxidant | - |
dc.subject.local | Anti-oxidant | - |
dc.subject.local | antioxidants | - |
dc.subject.local | ANTIOXIDANT | - |
dc.subject.local | anti-oxidants | - |
dc.subject.local | Antioxidant | - |
dc.subject.local | Arachidonate 5-lipoxygenase | - |
dc.subject.local | atherosclerosis | - |
dc.subject.local | Atherosclerosis | - |
dc.subject.local | atheroclerosis | - |
dc.subject.local | Endothelial cell | - |
dc.subject.local | endothelial cells | - |
dc.subject.local | endothelial cell | - |
dc.subject.local | Endothelial cells | - |
dc.subject.local | macrophages | - |
dc.subject.local | macrophage | - |
dc.subject.local | Macrophages | - |
dc.subject.local | Macrophage | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.